Eye Melanoma Companies
Companies involved in the field of eye melanoma, also known as ocular melanoma, may include those specializing in diagnostics, treatments, and research related to this type of cancer.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Â
Latest Eye Melanoma Companies Update
iOnctura Receives IND Approval for Uveal Melanoma Treatment: Swiss company iOnctura received FDA Investigational New Drug (IND) approval for roginolisib, a PI3K/AKT/mTOR inhibitor for uveal melanoma. This paves the way for Phase I clinical trials.
Meru Biosciences Licenses MCLA-145 for Eye Melanoma: Meru Biosciences entered a licensing agreement with OncoMed Pharmaceuticals for MCLA-145, a SHP2 inhibitor with potential for treating uveal melanoma and other cancers.
EyePoint Pharmaceuticals Initiates Phase 2 Trial for Y-mAbs Therapitics: EyePoint Pharmaceuticals began a Phase 2 trial evaluating the safety and efficacy of Y-mAbs Therapitics' anti-PD-1 antibody, YH001, in combination with standard therapy for uveal melanoma.
Roche Presents Positive Data on Tecentriq for Eye Melanoma: Roche presented encouraging data from a Phase 2 study demonstrating the potential of Tecentriq (atezolizumab), an anti-PD-L1 antibody, in combination with Zelboraf (vemurafenib) for treating metastatic uveal melanoma.
List of Eye Melanoma Key Companies in the Market
- Castle Biosciences Inc. (U.S.)
- GENERAL ELECTRIC (U.S.)
- Koninklijke Philips N.V. (The Netherlands)
- TOSHIBA CORPORATION (Japan)
- Siemens AG (Germany)
- Analogic Corporation (U.S.)
- Optovue
- Incorporated (U.S.)
- NOVADAQ Technologies Inc. (Canada)
- Agfa-Gevaert Group (Belgium)
- and ZEISS (Germany)
Eye Melanoma Market Highlights:
Eye Melanoma Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
